Parkinson’s took over the no. 1 spot for the most rapidly growing neurological disease.
https://www.foxnews.com/health/parkinso ... ates-study
Parkinsons
-
sgtski1010
- Posts: 1328
- Joined: Fri Mar 18, 2022 3:43 pm
- Has thanked: 18 times
- Been thanked: 85 times
-
cablejohn45
- Posts: 497
- Joined: Fri Mar 18, 2022 3:45 pm
- Location: K-T TX
- Has thanked: 119 times
- Been thanked: 147 times
Re: Parkinsons
Definitive Evidence of the Gut Microbiome Role in Parkinson’s Disease.
https://www.theepochtimes.com/health/de ... 81816.html
New research published in Nature Communications reveals widespread dysbiosis (disruption to the gut microbiome) in Parkinson’s sufferers and includes details of the specific microscopic species that are driving the imbalance.
Parkinson’s disease afflicts more than 10 million people worldwide, according to the Parkinson’s Foundation; in the United States alone, nearly 90,000 cases are diagnosed annually with an expected rise to 1.2 million by 2030, the organization says.
Parkinson’s is a disease that affects the nervous system and causes uncontrollable body movements including shaking and stiffness and difficulty with balance and coordination. Symptoms gradually increase with age and in later stages can affect brain function, causing dementia-like symptoms and depression.
In many cases, the findings confirm previous animal studies, but also may explain disease-specific mechanisms that weren’t necessarily linked to the microbiome. The metagenomics study (study of all genetic material sampled from a community) collected stool from 490 persons with Parkinson’s and 234 neurologically healthy controls.
Led by Haydeh Payami, founder and lead investigator of the NeuroGenetics Research Consortium at the University of Alabama–Birmingham, it’s the largest microbiome study conducted at the highest resolution, according to the university media office. It offers more specific insight into gut microorganisms, including a profile of the various pathogens associated with Parkinson’s, plus a chance to see the microbiomes of those who are neurologically healthy in detail.
The microbiome is an emerging field of study that’s composed of the dynamic microscopic world of organisms that, in this study, refers to the community living in the intestine. The human microbiome involves bacteria, viruses, and fungi on the skin and in organs. The gut microbiome has largely become associated with the body’s immune system and its role in pathogenic disease.
The study strengthens a hypothesis made in 2003 that non-familial forms of Parkinson’s begin in the gut. Largely considered a genetic brain disorder, Parkinson’s is often recognized by symptoms of uncontrollable movement such as tremors, as well as difficulties with balance and coordination. But it’s also associated with gastrointestinal distress such as constipation, inflammation, and a compromised gut barrier.
Among the study’s highlights as it related to those with Parkinson’s:
More than 30 percent of species, genes, and pathways tested had altered abundances.
Microbes tended to form polymicrobial clusters that grew or shrunk together, and some competed.
Microbiomes were in a state vulnerable to disease, with an overabundance of pathogens and immunogenic components.
Microbiomes tended to have dysregulated neuroactive signaling.
Microbiomes had a preponderance of molecules that induce alpha-synuclein pathology, a marker of the disease that’s related to cognitive functioning and implicated in neuronal dysfunction and death.
Microbiomes had an over-production of toxicants, with a reduction in anti-inflammatory and neuroprotective factors.
With these relationships established, it opens the door for further research on specific hypotheses. If the origin and progression of the disease can be pinpointed, that might lead to early diagnostic tools, as well as strategies to manipulate the microbiome for treatments and even prevention. The dataset is free and open to the public domain for use in more studies.
“We validate, in human Parkinson’s disease, findings that were observed in experimental models; reconcile and resolve human Parkinson’s disease microbiome literature; and provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in Parkinson’s disease,” the study says.
In all, the researchers looked at 257 different microbiome species, and more than 30 percent were associated with Parkinson’s. Of those 84 species, 55 were abnormally high and 29 were depleted.
Bifidobacterium dentium was elevated sevenfold; Actinomyces oris was elevated more than sixfold; and Streptococcus mutans was elevated sixfold, according to the university news release. Of those with low levels, Roseburia intestinalis was reduced by more than sevenfold and Blautia wexlerae by fivefold. In all, 36 percent of the species associated with Parkinson’s had higher than twofold change in abundance, reflecting a 100 percent to 750 percent increase or decrease in Parkinson’s versus the healthy group.
Metagenomics is a relatively new field but is rapidly developing technology that’s becoming more accessible and affordable. However, the existence of information only offers inference, as the metabolic functions aren’t observed in action. In this instance, there’s a lot of data that can help direct the scope of future research toward understanding microbial life.
https://www.theepochtimes.com/health/de ... 81816.html
New research published in Nature Communications reveals widespread dysbiosis (disruption to the gut microbiome) in Parkinson’s sufferers and includes details of the specific microscopic species that are driving the imbalance.
Parkinson’s disease afflicts more than 10 million people worldwide, according to the Parkinson’s Foundation; in the United States alone, nearly 90,000 cases are diagnosed annually with an expected rise to 1.2 million by 2030, the organization says.
Parkinson’s is a disease that affects the nervous system and causes uncontrollable body movements including shaking and stiffness and difficulty with balance and coordination. Symptoms gradually increase with age and in later stages can affect brain function, causing dementia-like symptoms and depression.
In many cases, the findings confirm previous animal studies, but also may explain disease-specific mechanisms that weren’t necessarily linked to the microbiome. The metagenomics study (study of all genetic material sampled from a community) collected stool from 490 persons with Parkinson’s and 234 neurologically healthy controls.
Led by Haydeh Payami, founder and lead investigator of the NeuroGenetics Research Consortium at the University of Alabama–Birmingham, it’s the largest microbiome study conducted at the highest resolution, according to the university media office. It offers more specific insight into gut microorganisms, including a profile of the various pathogens associated with Parkinson’s, plus a chance to see the microbiomes of those who are neurologically healthy in detail.
The microbiome is an emerging field of study that’s composed of the dynamic microscopic world of organisms that, in this study, refers to the community living in the intestine. The human microbiome involves bacteria, viruses, and fungi on the skin and in organs. The gut microbiome has largely become associated with the body’s immune system and its role in pathogenic disease.
The study strengthens a hypothesis made in 2003 that non-familial forms of Parkinson’s begin in the gut. Largely considered a genetic brain disorder, Parkinson’s is often recognized by symptoms of uncontrollable movement such as tremors, as well as difficulties with balance and coordination. But it’s also associated with gastrointestinal distress such as constipation, inflammation, and a compromised gut barrier.
Among the study’s highlights as it related to those with Parkinson’s:
More than 30 percent of species, genes, and pathways tested had altered abundances.
Microbes tended to form polymicrobial clusters that grew or shrunk together, and some competed.
Microbiomes were in a state vulnerable to disease, with an overabundance of pathogens and immunogenic components.
Microbiomes tended to have dysregulated neuroactive signaling.
Microbiomes had a preponderance of molecules that induce alpha-synuclein pathology, a marker of the disease that’s related to cognitive functioning and implicated in neuronal dysfunction and death.
Microbiomes had an over-production of toxicants, with a reduction in anti-inflammatory and neuroprotective factors.
With these relationships established, it opens the door for further research on specific hypotheses. If the origin and progression of the disease can be pinpointed, that might lead to early diagnostic tools, as well as strategies to manipulate the microbiome for treatments and even prevention. The dataset is free and open to the public domain for use in more studies.
“We validate, in human Parkinson’s disease, findings that were observed in experimental models; reconcile and resolve human Parkinson’s disease microbiome literature; and provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in Parkinson’s disease,” the study says.
In all, the researchers looked at 257 different microbiome species, and more than 30 percent were associated with Parkinson’s. Of those 84 species, 55 were abnormally high and 29 were depleted.
Bifidobacterium dentium was elevated sevenfold; Actinomyces oris was elevated more than sixfold; and Streptococcus mutans was elevated sixfold, according to the university news release. Of those with low levels, Roseburia intestinalis was reduced by more than sevenfold and Blautia wexlerae by fivefold. In all, 36 percent of the species associated with Parkinson’s had higher than twofold change in abundance, reflecting a 100 percent to 750 percent increase or decrease in Parkinson’s versus the healthy group.
Metagenomics is a relatively new field but is rapidly developing technology that’s becoming more accessible and affordable. However, the existence of information only offers inference, as the metabolic functions aren’t observed in action. In this instance, there’s a lot of data that can help direct the scope of future research toward understanding microbial life.
sgtski1010 wrote: ↑Thu Dec 29, 2022 6:51 am Parkinson’s took over the no. 1 spot for the most rapidly growing neurological disease.
https://www.foxnews.com/health/parkinso ... ates-study
-
sgtski1010
- Posts: 1328
- Joined: Fri Mar 18, 2022 3:43 pm
- Has thanked: 18 times
- Been thanked: 85 times
Re: Parkinsons
This is the year for a change. Parkinson disease has destroyed so many lives. I think that this disease needs a cocktail approach. First is to get it to freeze in place and then treatment to bring it back to minimal affect. Just my opinion.
-
sgtski1010
- Posts: 1328
- Joined: Fri Mar 18, 2022 3:43 pm
- Has thanked: 18 times
- Been thanked: 85 times
-
TimGDixon
- Posts: 4880
- Joined: Fri Mar 18, 2022 12:00 pm
- Has thanked: 338 times
- Been thanked: 320 times
Re: Parkinsons
https://patents.justia.com/patent/20230010501sgtski1010 wrote: ↑Sat Mar 18, 2023 3:38 pm This recent and relevant.
https://www.scitechdaily.com/scientists ... s-disease/
“...never interrupt your enemy when he is making mistakes...”
Re: Parkinsons
Tim, I read the article you posted previously on Parkinson's. Would it be possible for me to PM you?
-
TimGDixon
- Posts: 4880
- Joined: Fri Mar 18, 2022 12:00 pm
- Has thanked: 338 times
- Been thanked: 320 times
Re: Parkinsons
Hey Coach,
Yeah you can just PM here by clicking on my profile.
“...never interrupt your enemy when he is making mistakes...”